Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials

Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008688. doi: 10.1161/CIRCEP.120.008688. Epub 2020 May 21.

¹ Division of Hematology and Oncology, Mayo Clinic, Rochester, MN (O.O.).
² Division of Cardiology, Department of Medicine, University of California at Los Angeles (E.H.Y.).
³ Center for Cardiovascular Analytics, Research and Data Science (CARDS), Providence Heart Institute, Providence St Joseph Health, Portland, OR (T.J.G.).
⁴ The Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD (E.D.M., R.S.B.).
⁵ Department of Cardiovascular Medicine, Mayo Clinic & Mayo Clinic College of Medicine, Rochester, MN (B.J.G.).

No abstract available

Keywords: COVID-19; chloroquine; hydroxychloroquine; pandemic; trophozoites.

Publication types